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Despite the major role of the AKT/PKB family of proteins in the regulation of many growth and survival mechanisms in the cell, and
the increasing evidence suggesting that AKT disruption could play a key role in many human malignancies, no major mutations of AKT
genes had been reported, until very recently when Carpten et al reported a novel transforming mutation (E17K) in the pleckstrin
homology domain of the AKT1 gene in solid tumours. Several laboratories are now screening for this mutation in different
malignancies, and, recently, the mutation was described by Malanga et al in 1.9% of lung cancer patients. Considering the importance
of the PI3K/AKT pathway in mediating survival and antiapoptotic signals in the B-cell types of chronic lymphocytic leukaemia (CLL)
and acute lymphoblastic leukaemia (ALL), we sequenced the AKT1 exon 3 for the above mentioned mutation in 87 specimens,
representing 45 CLLs, 38 ALLs and 4 prolymphocytic leukaemia (PLL) cases, which are all of B-cell origin. Our results show that the
mutation E17K/AKT1 was not detected in the pleckstrin homology domain of AKT1 of the investigated cases. We conclude that this
mutation is not a major event in B-cell-derived lymphoid leukaemias.
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The v-akt murine thymoma viral oncogene homologue (AKT)
is a well-established survival factor exerting variable activities,
including cell survival, growth, proliferation, metabolism and
glucose uptake (Nicholson and Anderson, 2002; Elstrom et al,
2004; Hanada et al, 2004; Manning and Cantley, 2007). Mounting
evidence is showing the importance of AKT proteins in human
malignancies (Testa and Bellacosa, 2001; Altomare and Testa, 2005;
Bellacosa et al, 2005; Plas and Thompson, 2005). One of the
first such indications was provided by the isolation of a novel
transforming retrovirus ‘AKT-8’ from an AKR mouse T-cell
lymphoma (Staal et al, 1977). This transforming retrovirus was
subsequently shown to contain an intact viral oncogenic sequence
called v-akt (Staal and Hartley, 1988). Since then, many
studies have described perturbations of the AKT signalling
pathway in multiple human cancers, which have been reviewed
elsewhere (Altomare and Testa, 2005). However, mutational
analysis attempted to find any genetic abnormalities of
AKT kinase domains in common human malignancies revealed
no major genomic alterations in the three AKT isoforms
(Soung et al, 2006), although some reports described some minor
alterations in some of the isoforms associated with specific
malignancies (Robertson et al, 2005).
In July 2007, Carpten et al published a very interesting
study on the AKT1 gene in Nature, where they detected
a novel transforming mutation involving a glutamic acid (E) to
lysine (K) substitution at amino acid 17 (E17K) in the
pleckstrin homology domain of the AKT1 gene. This E17K
point mutation was identified in 8% of breast cancers, 6% of
colorectal cancers and 2% of ovarian cancers (Carpten et al, 2007).
Screening studies to find this novel mutation in other cancers
were carried out by different investigators in the past few
months. Although Tibes et al (2008) and Schu ¨ller et al
(2008) did not find the mutation in acute myeloid leukaemia,
and glioblastomas and medulloblastomas, respectively, the
mutation was detected in 1.9% of lung cancers; where it
represented 5.5% of the squamous cell carcinoma histotype
(Malanga et al, 2008).
Chronic lymphocytic leukaemia (CLL) is the most common
type of leukaemia in older adults in the West (Inamdar and
Bueso-Ramos, 2007). Chromosome defects are the most
common genetic abnormalities seen in CLL, and the last decades
have seen much progress in delineating the role of these
genetic aberrations in the pathogenesis of CLL (Cotter and Auer,
2007). However, the genetics of CLL is still not fully understood.
The PI3K/AKT pathway has been shown to play a central
role in promoting cell survival and growth of B-cell CLL (Barraga ´n
et al, 2002, 2006; Cunı ´ et al, 2004; Petlickovski et al, 2005;
Longo et al, 2007). Also, in a recent study, Longo et al
(2008) described the critical role of AKT in mediating the
antiapoptotic signals along with Mcl-1 downstream of the B-cell
receptor in CLL. Similarly, AKT has been described to mediate
survival of precursor B-acute lymphoblastic leukaemia (pre-B-
ALL) cells through activation of RAFTK, which plays an
antiapoptotic role (Sarkar et al, 2002). Also, Wang et al (2004)
have showed the pivotal role of Akt in mediating stromal cell
regulation of ALL cell apoptosis.
Considering the central role of AKT in CLL and ALL, we
performed a screening study in an attempt to detect the mutation
E17K/AKT1 in these types of haematological malignancies.
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sPATIENTS, MATERIALS AND METHODS
Patient samples
A total of 87 EDTA–blood samples (45 CLLs, 38 ALLs and 4
prolymphocytic leukaemias (PLLs)) were collected from Jordanian
patients attending King Hussein Cancer Center and Jordan
University hospital, according to protocols approved by the
Institutional Review Board. Informed consent was obtained from
each patient.
The CLL specimens represented all stages of the Rai staging
system (Rai et al, 1975), which was available for 41 out of 45
patients, whereas all ALL and PLL specimens were of the B-cell
type (Table 1).
Materials and methods
DNA was extracted from whole-blood samples using the Wizard
genomic DNA purification kit (Promega, Madison, WI, USA).
Polymerase chain reaction (PCR) was used to amplify genomic
DNA encompassing the coding sequences and intronic borders of
exon 3 of the AKT1 gene in patients’ DNA. The primers used for
PCR were the same as those used by Carpten et al (2007) (F: 50-
ACATCTGTCCTGGCACAC-30,R :5 0-GCCAGTGCTTGTTGCTTG-30).
The PCR was performed in 50ml reaction containing 200ng of
genomic DNA, 200mM dNTPs, 1.5mM MgCl2,1 UG oTaq
polymerase (Promega) and 10pmol of each primer (Invitrogen,
Carlsbad, CA, USA). The reaction conditions were as follows:
initial denaturation of 3min at 951C, followed by 34 cycles of 30s
at 951C, 30s at 521C, 1min at 721C and a final extension of 6min at
721C. The PCR products were purified using the Wizard SV gel and
PCR cleanup system (Promega) and then sequenced using the
same PCR primers. The sequencing reactions were performed at
Macrogen Inc., (Seoul, South Korea) using the Big Dyet
terminator cycle sequencing kit (Applied Biosystems, Foster Ctiy,
CA, USA) and the ABI 3730 XL analyzer (Applied Biosystem).
RESULTS AND DISCUSSION
The sequencing analysis for exon 3 of the human AKT1 gene in 87
samples (45 CLLs, 38 pre-B-cell ALLs and 4 B-cell PLLs) revealed
the absence of the point mutation G4A at nucleotide 49 (E17K),
which was first identified by Carpten et al (2007).
The genetic abnormalities seen in CLL differ from most other
forms of haematological malignancies, including ALL. Although
CLL is usually characterised by chromosomal deletions (Cotter and
Auer, 2007), ALL and many other forms of leukaemia usually
harbour chromosomal translocations in a significant number of
transformed cells. Despite the extensive sequencing analysis over
the last decade, no major point mutations have been identified in
CLL or ALL.
Because of the oncogenic potential of the mutation E17K, and its
ability to specifically induce B-cell leukaemia in mice (Carpten
et al, 2007), in addition to the importance of AKT proteins in
mediating survival and antiapoptotic signals in B-cell lineages of
CLL and ALL, we sought to look for this mutation in B-cell
lymphoid leukaemia patients. The CLL patients who were included
in this study represented the stable or advanced stages of the
disease; all ALL patients were of the pre-B-cell type and four
patients with PLL were also included.
From our findings we conclude that the mutation E17K/AKT1 is
unlikely to cause major transforming activity in B-cell-origin CLL,
ALL and PLL. However, given the small size of the sample
analysed, another large-scale study could increase the statistical
power of our results. Also, we did not include the T-lineage cells of
ALL in this study, which is something we will be working on next,
as it is worthwhile to screen for the mutation in this subclass of
acute leukaemia.
This report assesses the presence of E17K/AKT1 in B-cell
lymphoid leukaemias, including the chronic and acute phases. Our
results are supported by two recent reports, which were published
while preparing this paper, by Kim et al (2008) and Zenz et al
(2008), who also came to a similar conclusion regarding the
significance of E17K/AKT1 in B-cell ALL and CLL, respectively.
Further work is needed to investigate the possibility of analogous
mutations in other AKT isoforms as well as to detect the status of
this mutation in other related haematological malignancies.
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